Drug Prices

The “big three” pharmacy benefit managers have imposed markups ranging from 100% to more than 7,000% on generic specialty drugs dispensed at their affiliated pharmacies, according to a Federal Trade Commission report released this year.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent — for billions in profits, according to a report from the Federal Trade Commission, or FTC.

The largest retailer in the nation has sampled a taste of the autoimmune specialty pharmacy market, and has decided it wants more.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.

The top Healio blogs in ophthalmology last year explored the future of drug prices in the wake of the Inflation Reduction Act and important tips for avoiding Stark Law violations.

The manufacturers of the initial 10 drugs chosen for Medicare’s price negotiations have agreed to participate, the White House announced.

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

Researchers reported quadruple therapy with SGLT2 and angiotensin receptor-neprilysin inhibition was narrowly cost-effective compared with standard care plus SGLT2 inhibition alone for patients with HF and reduced ejection fraction.

Since 2010, nearly $1 trillion has flooded the U.S. health care system, across multiple specialties, from private equity firms through thousands of deals to acquire hospitals and practices.